{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T12:17:52Z","timestamp":1766837872472,"version":"3.44.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.annder.2018.01.047","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:43:51Z","timestamp":1524012231000},"page":"313-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Toxicit\u00e9s dermatologiques des inhibiteurs de checkpoint immunologiques"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-6633","authenticated-orcid":false,"given":"V.","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boulinguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Riffaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boyrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vigarios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2018.01.047_bib0005","first-page":"3017","article-title":"Supportive care for patients undergoing immunotherapy","volume":"25","author":"Rapoport","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0010","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0015","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1\u00a0and anti-PD-L1\u00a0immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0020","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0025","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annder.2018.01.047_bib0035","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0040","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0045","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1\u00a0immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0050","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1\u00a0receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0060","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0070","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0085","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side effects of anti-PD-1\u00a0therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0095","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0100","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1\u00a0therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0120","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1\u00a0and anti-programmed cell death ligand 1\u00a0immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.annder.2018.01.047_bib0125","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-pd-1\u00a0therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/DAD.0000000000000587","article-title":"Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without ipilimumab","volume":"39","author":"Chou","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2018.01.047_bib0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1\u00a0and anti-PD-1\u00a0therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2018.01.047_bib0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1\u00a0therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2018.01.047_bib0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1\u00a0expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2018.01.047_bib0155","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CMR.0000000000000261","article-title":"Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0165","article-title":"Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab","author":"Page","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.01.047_bib0170","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4\u00a0therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2018.01.047_bib0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1\u00a0antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2018.01.047_bib0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2016.11.002","article-title":"Inverse lichenoid drug eruption associated with nivolumab","volume":"3","author":"Guggina","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0185","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1\u00a0therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.01.047_bib0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0195","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1\u00a0therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0200","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0205","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annder.2016.08.003","article-title":"Psoriasis et arthrite psoriasique induits par le nivolumab (Opdivo\u00ae)","volume":"143","author":"Schmutz","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.01.047_bib0210","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21\u00a0patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.01.047_bib0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apm.12658","article-title":"Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome","volume":"125","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"APMIS"},{"key":"10.1016\/j.annder.2018.01.047_bib0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6\u00a0is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.annder.2018.01.047_bib0225","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0230","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1\u00a0blockade augments Th1\u00a0and Th17\u00a0and suppresses Th2\u00a0responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.annder.2018.01.047_bib0235","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/bjd.13058","article-title":"First report of ipilimumab-induced Grover disease","volume":"171","author":"Munoz","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-016-0151-z","article-title":"Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-016-0157-6","article-title":"A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4\u00a0but not PD-1","volume":"4","author":"Uemura","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0250","article-title":"Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy","author":"Sibaud","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.annder.2018.01.047_bib0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0260","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0265","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis","author":"Dai","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0275","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1\u00a0therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: a growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.annder.2018.01.047_bib0285","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1\u00a0and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0290","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1\u00a0protein inhibitor","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.01.047_bib0295","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0300","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0305","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0310","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-016-0123-3","article-title":"Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid","volume":"4","author":"Beck","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0315","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CMR.0000000000000287","article-title":"Antiepidermis autoantibodies induced by anti-PD-1\u00a0therapy in metastatic melanoma","volume":"26","author":"Brunet-Possenti","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0320","first-page":"195","article-title":"Drug-induced dermatomyositis following ipilimumab therapy","volume":"151","author":"Sheik","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0325","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0330","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0335","first-page":"43","article-title":"Onset of connective tissue disease following anti-PD-1\/PD-L1\u00a0cancer immunotherapy","volume":"76","author":"Le burel","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2018.01.047_bib0340","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-017-3313-6","article-title":"Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade","volume":"17","author":"Gambichler","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0345","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2018.01.047_bib0355","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0360","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0365","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary sarcoid-like granulomatosis induced by ipilimumab","volume":"30","author":"Berthod","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0370","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.annder.2018.01.047_bib0375","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216217","article-title":"Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition","volume":"2016","author":"Kim","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0380","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/dth.12380","article-title":"Cutaneous sarcoidosis in a melanoma patient under ipilimumab therapy","volume":"29","author":"Mart\u00ednez Lebor\u00e1ns","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2018.01.047_bib0385","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0390","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2018.01.047_bib0395","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1\u00a0checkpoint inhibitors: case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.annder.2018.01.047_bib0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1165\/rcmb.2016-0037OC","article-title":"Programmed death-1\u00a0inhibition of phosphatidylinositol 3-kinase\/AKT\/mechanistic target of rapamycin signaling impairs sarcoidosis CD4+ T cell proliferation","volume":"56","author":"Celada","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.annder.2018.01.047_bib0405","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0410","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2014.06.042","article-title":"Ipilimumab-associated Sweet syndrome in a melanoma patient","volume":"71","author":"Gormley","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0415","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jaad.2013.11.022","article-title":"Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma","volume":"70","author":"Kyllo","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0420","doi-asserted-by":"crossref","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"Plos One"},{"key":"10.1016\/j.annder.2018.01.047_bib0425","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0430","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2018.01.047_bib0435","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atelizumab, an anti-programmed death-ligand 1\u00a0antibody, in metastatic renal cell carcinoma: long term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0440","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2340\/00015555-2566","article-title":"Development of Papulopustular Rosacea during nivolumab therapy for metastatic cancer","volume":"97","author":"Bousquet","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2018.01.047_bib0445","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0450","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/CMR.0000000000000191","article-title":"Acute skin reaction suggestive of pembrolizumab-induced radiosensitization","volume":"25","author":"Sibaud","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2018.01.047_bib0455","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0460","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2017.2106","article-title":"Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1\u00a0and anti-programmed cell death ligand 1\u00a0agent for lung cancer","volume":"153","author":"Rivera","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2018.01.047_bib0465","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/annonc\/mdw543","article-title":"Pembrolizumab induced severe sclerodermoid reaction","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0470","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.04.007","article-title":"Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature","volume":"108","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annder.2018.01.047_bib0475","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3747\/co.20.1265","article-title":"Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases","volume":"20","author":"Assi","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.annder.2018.01.047_bib0480","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/1078155216674355","article-title":"Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer","volume":"23","author":"Dasanu","year":"2016","journal-title":"J Oncol Pharm Pract"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963818301303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963818301303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:06:29Z","timestamp":1758971189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963818301303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0151963818301303"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2018.01.047","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9s dermatologiques des inhibiteurs de checkpoint immunologiques","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2018.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}